Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 6/20 | 0.52 |
| ▸ | CTSL | P07711 | 6/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.41 |
| ▸ | PPIA | P62937 | 1/20 | 0.39 |
| ▸ | MYC | P01106 | 1/20 | 0.39 |
| ▸ | MAX | P61244 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PLK1 | P53350 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4279066 | 1.00 | CTSV (0.52) | CTSVCTSLCYP19A1PPIAMYC | |
| SCHEMBL3249526 | 0.92 | CTSV (0.47) | CTSVCTSLCYP19A1PPIAMYC | |
| SCHEMBL3607727 | 0.82 | CTSV (0.48) | CTSVCTSLCYP19A1PPIAMYC | |
| SCHEMBL3607732 | 0.82 | CTSV (0.48) | CTSVCTSLCYP19A1PPIAMYC | |
| SCHEMBL13462812 | 0.79 | CTSV (0.43) | CTSVCTSLMEN1MAPTKMT2A | |
| SCHEMBL3256473 | 0.74 | LRRK2 (0.47) | CTSVCTSLCYP19A1MYCMAX | |
| SCHEMBL3256470 | 0.74 | LRRK2 (0.47) | CTSVCTSLCYP19A1MYCMAX | |
| SCHEMBL3255304 | 0.74 | CTSV (0.44) | CTSVCTSLCYP19A1PPIAMYC | |
| SCHEMBL5008916 | 0.73 | ALDH1A1 (0.38) | CTSVCTSLCYP19A1MYCMAX | |
| SCHEMBL5008912 | 0.73 | ALDH1A1 (0.38) | CTSVCTSLCYP19A1MYCMAX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7615643-B2 | 3-[((1R)-1-{2-Chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl}ethyl)oxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-2-thiophenecarboxamide; polo like kinase enzyme inhibitors; anticarcinogenic agents for treating cancer | SMITHKLINE BEECHAM CORPORATION (US) | 2009-11-10 | — | — | US | disclosed |
| US-20090124615-A9 | Benzimidazole Thiophene Compounds | KUNTZ KEVIN | 2009-05-14 | — | — | US | disclosed |
| US-20080300247-A1 | Benzimidazole Thiophene Compounds | KUNTZ KEVIN | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124615-A9 | Benzimidazole Thiophene Compounds | ABCB1, CYP3A5, ABCG2 | CTSV 1741/4885CTSL 2218/4885CYP19A1 1755/4885 |
| US-20080300247-A1 | Benzimidazole Thiophene Compounds | ABCB1, CYP3A5, ABCG2 | CTSV 1741/4885CTSL 2218/4885CYP19A1 1755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.